AAV (ANCA-associated vasculitis) is a group of progressive, rare, severe autoimmune diseases1,2
AAV can affect blood vessels in different parts of the body resulting in damage to vital organs such as the lungs, kidneys, nervous system, gastrointestinal system, skin, eyes, and heart.2Read more
See how the interaction between neutrophils and the alternative complement system are at the heart of the vasculitic process in AAVMore information
Patient videos - view stories from Catherine, Jeremy, John & Susan and Shanali on the patient experience pageVideos
Join the Rare Disease Investigation Team and put your expertise to the test in our interactive challenge. You’ll find it’s fully compatible with most desktop and mobile/tablet browsers (not for use on older versions of Internet Explorer or on Microsoft Edge)
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis
Hutton HL, et al. Semin Nephrol 2017;37(5):418–35.
Al-Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34.
Jennette JC, et al. Arthritis Rheum 2013;65(1):1–11.
Yates M, Watts R. Clin Med (Lond) 2017;17(1):60–4.
Pagnoux C. Eur J Rheumatol 2016;3(3):122–33.
Adverse events and infections as major concerns with remission induction therapy of ANCA-associated vasculitis. Poster >
High burden of disease for AAV patients in Germany - a claims study. Poster >
Economic burden of ANCA-associated vasculitis in Germany - a claims data study. Poster >
Adverse events due to high-dose glucocorticoids - lessons from ANCA-associated vasculitis and other inflammatory diseases. Poster >
Severity and response to induction therapy in new and relapsing ANCA-associated vasculitis patients - real world practice data. Poster >
Renal damage in ANCA-associated vasculitis in incident and relapsing patients Slide deck >
Variable response to induction therapy and significant burden of treatment adverse events over the first 12 months of remission induction treatment in ANCA-associated vasculitis patients. Poster >